The current project is to explore feasibility of direct intra-renal injection of human bone marrow derived mesenchymal stem cells (hMSC) for treatment of lupus nephritis in mice. The treatment protocol involved aged male BXSB (20 weeks) injected with 1 × 106 hMSC unilaterally under the renal capsule. Mice were harvested after 10 weeks follow-up for postmortem exam. Controls included untreated age matched male BXSB and healthy C57Bl/6. At the end of follow-up period, the survival of treated BXSB was 10 folds higher at 62.5% compared to survival of untreated control at 6.3%. The survival of C57Bl/6 remained at 100% with or without similar treatment. The renal pathology review was most significant for decreased tissue inflammation in treated BXSB compared to untreated controls. Renal tissue expression of IL-1b, IL17 were decreased and CTLA-4 was increased by RT PCR among treated compared to untreated BXSB. Thus, direct delivery of hMSC by intrarenal injection is a promising route for treatment of lupus nephritis as shown in this xenogeneic model. Further studies -using expanded numbers of mice to include other lupus strains- are warranted to investigate the mechanisms involved and to optimize treatment protocol for safety and efficacy.
TsokosGC.Systemic lupus erythematosus. N Engl J Med2011;
365: 2110–2121.
2.
HooverPJCostenbaderKH.Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective. Kidney Int2016;
90: 487–492.
3.
HahnBH.Targeted therapies in systemic lupus erythematosus: successes, failures and future. Ann Rheum Dis2011;
70(Suppl 1): i64–i66.
4.
CaplanAICorreaD.The MSC: an injury drugstore. Cell Stem Cell2011;
9: 11–15.
5.
SunLAkiyamaKZhangH, et al.
Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells2009;
27: 1421–1432.
6.
CrasAFargeDCarmoiT, Lataillade JJ, Wang DD and Sun L.
Update on mesenchymal stem cell-based therapy in lupus and scleroderma. Arthritis Res Ther2015;
17: 301–309.
7.
LeyendeckerAJrPinheiroCCGAmanoMT and Bueno DF.
The use of human mesenchymal stem cells as therapeutic agents for the in vivo treatment of immune-related diseases: a systematic review. Front Immunol2018;
9: 2056–2105.
8.
KeyszerGChristopeitMFickS, et al.
Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases. Arthritis Rheum2011;
63: 2540–2542.
9.
WangLWangLCongX, et al.
Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. Stem Cells Dev2013;
22: 3192–3202.
10.
ForbesGMSturmMJLeongRW, et al.
A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol2014;
12: 64–71.
11.
SquillaroTPelusoGGalderisiU.Clinical trials with mesenchymal stem cells: an update. Cell Transplant2016;
25: 829–848.
12.
ZhouKZhangHJinO, et al.
Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol2008;
5: 417–424.
13.
ChangJWHungSPWuHH, et al.
Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis. Cell Transplant2011;
20: 245–257.
14.
BukulmezH.Mesenchymal stem cell treatment in mice models of systemic lupus erythematosus. In: TurksenK (ed.). Mesenchymal stem cells and immunomodulation in diseases, stem cell biology and regenerative medicine.
Totowa, NJ:
Humana Press, 2016, pp.25–42.
15.
LiuJLuXLouY, et al.
Xenogeneic transplantation of human placenta-derived mesenchymal stem cells alleviates renal injury and reduces inflammation in a mouse model of lupus nephritis. Biomed Res Int2019;
2019: 9370919–9370930.
16.
ChoiEWLeeMSongJW, Shin IS and Kim SJ.
Mesenchymal stem cell transplantation can restore lupus disease-associated miRNA expression and Th1/Th2 ratios in a murine model of SLE. Sci Rep2016;
6: 38237–38251.
17.
GuZAkiyamaKMaX, et al.
Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice. Lupus2010;
19: 1502–1514.
18.
ZhangWFengYLPangCY, Lu FA and Wang YF.
Transplantation of adipose tissue-derived stem cells ameliorates autoimmune pathogenesis in MRL/lpr mice: modulation of the balance between Th17 and Treg. Z Rheumatol2019;
78: 82–88.
19.
WangDZhangHLiangJ, et al.
Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant2013;
22: 2267–2277.
20.
WuCGZhangJCXieCQ, et al.
In vivo tracking of human placenta derived mesenchymal stem cells in nude mice via (1)(4)C-TdR labeling. BMC Biotechnol2015;
15: 55–63.
21.
ThompsonMMeiSHJWolfeD, et al.
Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine2020;
19: 100249–100265.
22.
FloreaVRiegerACDiFedeDL, et al.
Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (the TRIDENT study). Circ Res2017;
121: 1279–1290.
23.
PanesJGarcia-OlmoDVan AsscheG, et al.
Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn's disease. Gastroenterology2018;
154: 1334–1342.
24.
MoghadasaliRAzarniaMHajinasrollahM, et al.
Intra-renal arterial injection of autologous bone marrow mesenchymal stromal cells ameliorates cisplatin-induced acute kidney injury in a rhesus Macaque mulatta monkey model. Cytotherapy2014;
16: 734–749.
25.
BehrLHekmatiMFromontG, et al.
Intra renal arterial injection of autologous mesenchymal stem cells in an ovine model in the postischemic kidney. Nephron Physiol2007;
107: p65–76.
26.
KocONGersonSLCooperBW, et al.
Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol2000;
18: 307–316.
27.
IkeharaSGoodRANakamuraT, et al.
Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci U S A1985;
82: 2483–2487.
28.
JonesOYSteeleAJonesJM, et al.
Nonmyeloablative bone marrow transplantation of BXSB lupus mice using fully matched allogeneic donor cells from green fluorescent protein transgenic mice. J Immunol2004;
172: 5415–5419.
29.
DominiciMLe BlancKMuellerI, et al.
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy2006;
8: 315–317.
30.
AndrewsBSEisenbergRATheofilopoulosAN, et al.
Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med1978;
148: 1198–1215.
31.
SubramanianSTusKLiQZ, et al.
A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U S A2006;
103: 9970–9975.
32.
LiLNukalaSDuY, et al.
Murine lupus strains differentially model unique facets of human lupus serology. Clin Exp Immunol2012;
168: 178–185.
33.
JonesOYAlexanderPJLacsonA, et al.
Effects of fludarabine treatment on murine lupus nephritis. Lupus2004;
13: 912–916.
34.
WangBYCherry El-BadriNS, et al.
Prevention of development of autoimmune disease in BXSB mice by mixed bone marrow transplantation. Proc Natl Acad Sci U S A1997;
94: 12065–12069.
35.
JonesOYLacsonAZengX, et al.
Long-term follow-up after non-myeloablative transplant of bone and marrow in BXSB mice. Lupus2009;
18: 813–821.
36.
LeeCJangMJKimBH, et al.
Recovery of renal function after administration of adipose-tissue-derived stromal vascular fraction in rat model of acute kidney injury induced by ischemia/reperfusion injury. Cell Tissue Res2017;
368: 603–613.
37.
RodriguesCECapchaJMCde BragançaAC, et al.
Human umbilical cord-derived mesenchymal stromal cells protect against premature renal senescence resulting from oxidative stress in rats with acute kidney injury. Stem Cell Res Ther2017;
8: 19–35.
38.
QuimbyJMWebbTLGibbonsDS and Dow SW.
Evaluation of intrarenal mesenchymal stem cell injection for treatment of chronic kidney disease in cats: a pilot study. J Feline Med Surg2011;
13: 418–426.
39.
YasudaKOzakiTSakaY, et al.
Autologous cell therapy for cisplatin-induced acute kidney injury by using non-expanded adipose tissue-derived cells. Cytotherapy2012;
14: 1089–1100.
40.
AlfaranoCRoubeixCChaayaR, et al.
Intraparenchymal injection of bone marrow mesenchymal stem cells reduces kidney fibrosis after ischemia-reperfusion in cyclosporine-immunosuppressed rats. Cell Transplant2012;
21: 2009–2019.
41.
LaiPWengJGuoL, Chen X and Du X.
Novel insights into MSC-EVs therapy for immune diseases. Biomark Res2019;
7: 6–15.
42.
EirinAZhuXYFergusonCM, et al.
Intra-renal delivery of mesenchymal stem cells attenuates myocardial injury after reversal of hypertension in porcine renovascular disease. Stem Cell Res Ther2015;
6: 7–19.
